Exagen will pay Cypress up to $8 million in upfront and milestone payments as well as additional royalty payments for the business.
Under the deal, Marina will receive $750,000 up front, and stands to be paid as much as $27 million in milestones.
The firm offers its Avise PG test as a service for physicians making decisions about methotrexate therapy.
Cypress will pay up to $5 million for the technology, which it plans to use for diagnosis and therapeutic monitoring of lupus patients.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.